Table: Solasia Pharma -Q1 group results (IFRS)

Solasia Pharma KK

12/05/2021 07:30

May 12 (Reuters)- 
              Solasia Pharma K. K. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   3 months ended      3 months ended       Year to 
                  Mar 31, 2021        Mar 31, 2020     Dec 31, 2021 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              91 mln              156 mln                    
                   (-41.1 pct)        (+154.5 pct)                  
  Operating       loss 642 mln        loss 534 mln                  
  Pretax          loss 650 mln        loss 537 mln                  
  Net             loss 656 mln        loss 531 mln                  
  EPS Basic       loss 5.22 yen       loss 4.57 yen                 
  EPS Diluted     loss 5.22 yen       loss 4.57 yen                 
  Ann Div                                  NIL              NIL     
  -Q2 Div                                  NIL              NIL     
  -Q4 Div                                  NIL              NIL     
 
  NOTE - Solasia Pharma K. K.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4597.T